S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NASDAQ:PRAX

Praxis Precision Medicines (PRAX) Competitors

$0.88
+0.02 (+2.33%)
(As of 06/1/2023 ET)
Compare
Today's Range
$0.83
$0.90
50-Day Range
$0.80
$1.12
52-Week Range
$0.79
$8.75
Volume
505,675 shs
Average Volume
1.52 million shs
Market Capitalization
$54.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

PRAX vs. GLTO, CLSD, VIRX, IMNM, IPA, LGVN, FBIO, SCTL, CNTB, and ADAG

Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Galecto (GLTO), Clearside Biomedical (CLSD), Viracta Therapeutics (VIRX), Immunome (IMNM), ImmunoPrecise Antibodies (IPA), Longeveron (LGVN), Fortress Biotech (FBIO), Societal CDMO (SCTL), Connect Biopharma (CNTB), and Adagene (ADAG). These companies are all part of the "pharmaceutical preparations" industry.

Praxis Precision Medicines vs.

Praxis Precision Medicines (NASDAQ:PRAX) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.

Galecto is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/A-$214.03 million-$3.86-0.23
GalectoN/AN/A-$61.62 million-$2.27-0.94

Galecto received 14 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. Likewise, 62.79% of users gave Galecto an outperform vote while only 52.00% of users gave Praxis Precision Medicines an outperform vote.

CompanyUnderperformOutperform
Praxis Precision MedicinesOutperform Votes
13
52.00%
Underperform Votes
12
48.00%
GalectoOutperform Votes
27
62.79%
Underperform Votes
16
37.21%

89.3% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 35.8% of Galecto shares are held by institutional investors. 10.5% of Praxis Precision Medicines shares are held by insiders. Comparatively, 9.2% of Galecto shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Praxis Precision Medicines currently has a consensus price target of $10.25, indicating a potential upside of 1,068.62%. Galecto has a consensus price target of $11.67, indicating a potential upside of 445.17%. Given Praxis Precision Medicines' higher probable upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Galecto.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Galecto
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Praxis Precision Medicines has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Galecto has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

In the previous week, Galecto had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 2 mentions for Galecto and 0 mentions for Praxis Precision Medicines. Galecto's average media sentiment score of 0.75 beat Praxis Precision Medicines' score of 0.00 indicating that Galecto is being referred to more favorably in the news media.

Company Overall Sentiment
Praxis Precision Medicines Neutral
Galecto Positive

Galecto's return on equity of -85.49% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Praxis Precision Medicines N/A -190.08% -137.72%
Galecto N/A -85.49% -73.78%

Summary

Galecto beats Praxis Precision Medicines on 10 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRAX vs. The Competition

MetricPraxis Precision MedicinesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$54.47M$5.82B$4.54B$6.20B
Dividend YieldN/A2.74%2.42%6.15%
P/E Ratio-0.234.87100.6311.94
Price / SalesN/A326.473,636.6695.58
Price / CashN/A20.1190.91108.26
Price / Book0.845.435.157.27
Net Income-$214.03M$190.11M$117.81M$193.48M
7 Day Performance-13.59%8.11%3.21%2.60%
1 Month Performance-21.69%7.79%3.14%3.08%
1 Year Performance-89.14%23.71%23.11%1.73%

Praxis Precision Medicines Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLTO
Galecto
1.9323 of 5 stars
$2.67
flat
$11.67
+337.8%
+66.4%$68.41MN/A-1.1728Gap Up
CLSD
Clearside Biomedical
1.8858 of 5 stars
$1.10
+0.9%
$6.00
+445.5%
-16.9%$67.84M$1.33M-1.9334Gap Down
VIRX
Viracta Therapeutics
2.213 of 5 stars
$1.80
-9.5%
$8.00
+344.4%
-37.3%$69.14MN/A-1.3424Gap Up
High Trading Volume
IMNM
Immunome
2.1512 of 5 stars
$5.69
+11.6%
$8.00
+40.6%
+34.7%$69.53MN/A-2.2939Gap Up
IPA
ImmunoPrecise Antibodies
2.0259 of 5 stars
$2.84
+0.7%
$8.00
+181.7%
-44.9%$70.80M$15.32M-3.3873Gap Up
LGVN
Longeveron
1.8673 of 5 stars
$3.37
+3.1%
$12.50
+271.5%
-63.8%$70.93M$1.22M-3.5418
FBIO
Fortress Biotech
2.0275 of 5 stars
$0.53
flat
$5.50
+938.3%
-37.5%$71.18M$64.25M-0.53173Short Interest ↑
Gap Up
SCTL
Societal CDMO
2.108 of 5 stars
$0.85
+18.1%
$2.00
+135.3%
-5.1%$72.18M$90.21M-2.58N/AGap Up
CNTB
Connect Biopharma
2.4938 of 5 stars
$1.17
flat
$7.00
+498.3%
+35.5%$64.40MN/A0.0062Gap Down
ADAG
Adagene
2.0321 of 5 stars
$1.48
-1.3%
$5.00
+239.0%
-52.1%$63.88M$9.29M0.00198

Related Companies and Tools

This page (NASDAQ:PRAX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -